Composition for preventing, alleviating or treating alopecia or white hair by modulating aldehyde dehydrogenase 2

The promotion of hair follicle formation and hair growth through aldehyde dehydrogenase 2 activator has solved the effectiveness and safety of hair loss and gray hair treatment in the prior art. In particular, the effect of hair loss treatment is significantly improved when combined with minoxidil. Reduces the risk of side effects.

CN118973566APending Publication Date: 2024-11-15SEOUL NAT UNIV HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031016.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-15
Filing Date
2023-01-25
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art lacks effective and safe methods for preventing and treating hair loss and gray hair, especially minoxidil treatments with side effects need to be replaced, and existing therapeutic drugs have limited effect on female hair loss.

Method used

Promote hair follicle formation and hair growth by using aldehyde dehydrogenase 2 (ALDH2) activator and is used in combination with minoxidil to enhance the therapeutic effect of hair loss and reduce side effects.

Benefits of technology

Aldehyde dehydrogenase 2 activator can effectively promote hair follicle cell proliferation and hair growth, inhibit oxidative stress, significantly improve the prevention and treatment effect of hair loss when used alone or in combination with minoxidil, and exhibit versus minoxidil at low doses Nordil has the same or better effect, reducing the risk of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973566A_ABST
    Figure CN118973566A_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for preventing, alleviating and / or treating alopecia or poliosis (or limited poliosis) and the like, and is accomplished by confirming that an aldehyde dehydrogenase 2 (ALDH2) activator promotes hair follicle formation and hair growth and has an excellent effect of inhibiting oxidative stress of hair follicles. Thus, the ALDH2 activator according to the present invention can be used as a formulation for preventing, alleviating and / or treating alopecia and poliosis. In addition, the combined treatment of the ALDH2 activator and minoxidil shows better effects of preventing and treating alopecia. Therefore, ALDH2 according to the present invention is self-effective in promoting hair growth and is expected to be effectively used in combination with minoxidil in the fields of medical, cosmetic and food items to prevent, alleviate and treat alopecia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for preventing, alleviating or treating hair loss or gray hair, etc. by regulating aldehyde dehydrogenase 2. In addition, the present invention relates to a combination therapy for preventing, alleviating or treating hair loss by regulating aldehyde dehydrogenase 2.

[0002] The present invention claims priority to and the benefit of Korean Patent Application Nos. 10-2022-0011538, 10-2022-0079800 and 10-2022-0152981 filed in the Korean Intellectual Property Office on January 26, 2022, June 29, 2022 and November 15, 2022, respectively, and all contents disclosed in the specifications and drawings of these applications are incorporated into this application. Background Art

[0003] Hair follicles are organs that produce hair, and they repeat the hair cycle, which is divided into the anagen phase in which hair is produced and the produced hair actively grows, the catagen phase in which hair degenerates, the telogen phase in which hair is kept until it falls off, and the exogen phase in which hair loss occurs, and the hair follicles participate in the growth, maintenance, and shedding of hair. It is known that in the anagen phase of hair follicles, in adults, hair grows at an average rate of about 0.3 mm per day and about 1 cm per month, and continues to grow for about 5 to 8 years. Typically, hair falls off after the anagen phase, the catagen phase lasts about three weeks, and the telogen phase lasts an average of three months. The reason why human hair length differs between different regions is that the duration of the anagen phase, which is an intrinsic characteristic of hair follicles, is not the same between different regions.

[0004] Hair is formed in hair follicles. Hair follicles are a very complex organ, which consists of an inner root sheath, an outer root sheath, a hair shaft, hair matrix cells, etc., and in particular, hair dermal papilla cells play a key role in hair follicle formation and are therefore directly related to the ability to form hair follicles. When hair dermal papilla cells are missing or non-functional, hair follicles cannot be formed because proper interaction between hair dermal papilla cells and epidermal cells cannot occur.

[0005] Alopecia refers to a state in which there is little or no hair in a part where hair should normally be present. It is known that factors such as genetic causes or the influence of male hormones, endocrine disorders, malnutrition, drug use, and severe physical and mental stress such as childbirth, fever, and surgery are involved in hair loss in a complex manner. In recent years, due to reasons such as changes in diet and increased stress caused by the social environment, not only male pattern hair loss exists, but the number of women experiencing hair loss is also increasing, and therefore, the number of people suffering from abnormal symptoms of the scalp and hair is increasing, and the age of people suffering from these abnormal symptoms is also getting younger and younger.

[0006] Although the research on hair loss prevention and hair regeneration agents at home and abroad is accelerating, and various products are also under development, there is currently a lack of development of hair loss prevention agents with excellent efficacy and safety to the human body. The topical products currently developed include minoxidil in the United States and herbal extracts mainly developed by Japan as hair growth agents or hair regeneration agents, but it is too early to claim hair loss prevention and hair regeneration functions. In particular, it is reported that minoxidil can cause side effects such as weight gain, edema, increased heart rate, angina, dermatitis and itching when used in high doses. Therefore, it is necessary to explore a more effective hair loss therapeutic agent that can replace minoxidil or a combined therapy that can enhance the hair growth effect of minoxidil and reduce side effects.

[0007] Currently, the 5α-reductase inhibitors finasteride and dutasteride are almost the only effective treatments for male pattern baldness, but the treatment effects vary greatly between people, and hair loss may recur or serious side effects such as sexual dysfunction may occur when the product is stopped. In particular, since most of the existing hair loss treatments approved by the US FDA are drugs developed for male pattern hair loss, they have limitations in treating female pattern hair loss and are likely to cause side effects in women. Therefore, there is an urgent need to study new hair loss prevention agents and hair regrowth agents that can be proven to be safe and effective for both men and women.

[0008] Gray hair is one of the aging processes and occurs in various ways depending on the individual. Although the cause of gray hair is understood to be the loss or reduced activity of melanocytes in the hair bulb and outer root sheath, its cellular or molecular mechanism is still unclear. Melanocytes without melanin remain in the outer root sheath of gray hair, but are not found in the hair bulb, which indicates that melanocyte stem cells are reduced or the process regulating melanocyte migration and differentiation is abnormal. Melanocytes are located in the hair bulb of human hair follicles and begin to gather around the dermal papilla during the hair growth phase after division. Tyrosinase and TRP-1 enzymes expressed in melanocytes are only observed in the growth phase and are not produced in the mid-growth phase. Therefore, by periodically activating melanocytes in the growth phase, pigment can be regenerated in the hair at the top of the outer root sheath.

[0009] The accumulation of reactive oxygen species generated during melanin production can damage the antioxidant system, thereby inducing oxidative stress. Excessive oxidative stress is known to affect the production of melanocytes. In particular, accumulated oxidative stress may disrupt the homeostasis of melanocytes, leading to cell death or deformation. Therefore, in order to prevent or alleviate hair loss and graying, it is very important to inhibit oxidative stress in melanocytes.

[0010] Since gray hair gives a strong impression of aging, much research has been conducted on dyes that dye gray hair black to hide the gray hair that has already occurred. However, hair dyeing is only a temporary method, and since it is based on chemicals, it may damage the scalp and worsen the health of hair follicles. Therefore, there is a need to explore a new method that can prevent and alleviate gray hair from the root.

[0011] Meanwhile, aldehyde dehydrogenase 2 (ALDH2) is known to be an enzyme present in the mitochondria of the body, which normally converts acetaldehyde into acetic acid to help decompose alcohol absorbed in the body. However, the effect of activating the above enzyme on preventing hair loss or promoting hair regeneration has not been reported. Summary of the invention

[0012] [Technical issues]

[0013] The present invention is designed to solve the above problems and has been completed by confirming that aldehyde dehydrogenase 2 activators promote hair follicle formation and hair growth, thereby effectively preventing hair loss, promoting hair regeneration, and preventing or alleviating gray hair. In addition, it has been confirmed that aldehyde dehydrogenase 2 activators can show a synergistic hair loss treatment effect when used in combination with minoxidil.

[0014] The present invention aims to provide a pharmaceutical composition for preventing or treating hair loss or gray hair, wherein the composition comprises an aldehyde dehydrogenase 2 activator as an active ingredient.

[0015] The present invention aims to provide a cosmetic composition for preventing or alleviating hair loss or graying hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient.

[0016] The present invention also aims to provide a quasi-drug composition for preventing or alleviating hair loss or graying of hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient.

[0017] The present invention also aims to provide a food composition for preventing or alleviating hair loss or gray hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient. The food composition includes a health functional food composition.

[0018] The present invention also aims to provide a pharmaceutical composition for preventing or treating hair loss, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient, wherein the pharmaceutical composition is administered in combination with minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof.

[0019] The present invention also aims to provide a pharmaceutical composition for preventing or treating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof as active ingredients.

[0020] The present invention also aims to provide a cosmetic composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a cosmetically acceptable salt thereof or an analog thereof as active ingredients.

[0021] The present invention also aims to provide a quasi-drug composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof as active ingredients.

[0022] The present invention also aims to provide a food composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a food-acceptable salt thereof or an analog thereof as active ingredients.

[0023] The present invention also aims to provide a healthy functional food composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a food-acceptable salt thereof or an analog thereof as active ingredients.

[0024] However, the technical problems that the present invention is intended to solve are not limited to the above-mentioned technical problems, and a person of ordinary skill in the art to which the present invention belongs will clearly understand other technical problems not mentioned from the following description.

[0025] [Technical solution]

[0026] One aspect of the present invention provides a pharmaceutical composition for preventing or treating hair loss or graying hair, the composition comprising an aldehyde dehydrogenase 2 (ALDH2) activator as an active ingredient.

[0027] Another aspect of the present invention provides a method for preventing or treating hair loss or graying of hair, the method comprising administering an ALDH2 activator to a subject in need thereof.

[0028] Another aspect of the present invention provides use of an ALDH2 activator for preventing or treating hair loss or graying of hair.

[0029] Another aspect of the present invention provides use of an ALDH2 activator for preparing a medicament for treating hair loss or gray hair.

[0030] In an exemplary embodiment of the present invention, the composition may be used to promote hair growth or hair regeneration, but is not limited thereto.

[0031] In another exemplary embodiment of the present invention, the hair loss may be any one or more selected from the group consisting of alopecia areata, hereditary androgenic alopecia, telogen effluvium, traumatic alopecia, trichotillomania, compression alopecia, anagen effluvium, pityriasis alopecia, syphilitic alopecia, seborrheic alopecia, symptomatic alopecia and congenital alopecia, but is not limited thereto.

[0032] In another exemplary embodiment of the present invention, the aldehyde dehydrogenase 2 activator may be Alda-1 or a pharmaceutically acceptable salt thereof, but is not limited thereto.

[0033] In yet another exemplary embodiment of the present invention, Alda-1 or a pharmaceutically acceptable salt thereof may be included at a concentration of 0.0001 to 50 mM relative to the composition, but is not limited thereto.

[0034] In another exemplary embodiment of the present invention, the composition may satisfy one or more properties selected from but not limited to the group consisting of: (a) promoting the proliferation of hair dermal papilla cells or outer root sheath cells; (b) promoting the growth of hair follicles; (c) inducing the growth phase of hair; and (d) increasing mitochondrial activity.

[0035] In yet another exemplary embodiment of the present invention, the composition may increase the level or activity of one or more proteins selected from the group consisting of, but not limited to, bFGF, FGF-7, IGF-1, and PDGF.

[0036] In yet another exemplary embodiment of the present invention, the composition may reduce oxidative stress in hair dermal papilla cells or outer root sheath cells, but is not limited thereto.

[0037] Still another aspect of the present invention provides a cosmetic composition for preventing or alleviating hair loss or graying hair, the composition comprising an ALDH2 activator as an active ingredient.

[0038] In an exemplary embodiment of the present invention, the composition may be an external preparation in the form of a scalp care agent, soap, hair tonic, shampoo, hair dye, hair mask, hair gel, lotion, conditioner, hair oil, mousse, cream, solid, solution, emulsion, dispersion, micelle, liposome, ointment, perfume, essential oil, patch or spray, but is not limited thereto.

[0039] Still another aspect of the present invention provides a quasi-drug composition for preventing or alleviating hair loss or graying of hair, the composition comprising an ALDH2 activator as an active ingredient.

[0040] Still another aspect of the present invention provides a food composition for preventing or alleviating hair loss or graying hair, the composition comprising an ALDH2 activator as an active ingredient.

[0041] Still another aspect of the present invention provides a healthy functional food composition for preventing or alleviating hair loss or graying hair, the healthy functional food composition comprising the food composition as an active ingredient.

[0042] Another aspect of the present invention provides a method for preventing or alleviating gray hair, the method comprising administering an ALDH2 activator to a subject in need thereof. The method may be a cosmetic method.

[0043] Another aspect of the present invention provides use of an ALDH2 activator for preventing or alleviating gray hair.

[0044] Another aspect of the present invention provides use of an ALDH2 activator for preparing a medicament for preventing or alleviating gray hair.

[0045] Still another aspect of the present invention provides a pharmaceutical composition for preventing or treating hair loss, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient, which is administered in combination with minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

[0046] Another aspect of the present invention provides the use of an aldehyde dehydrogenase 2 activator in combination with minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof.

[0047] Yet another aspect of the present invention provides a method for preventing or treating hair loss, comprising administering to a subject in need thereof (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

[0048] Another aspect of the present invention provides use of a composition for preventing or treating hair loss, the composition comprising: (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

[0049] Another aspect of the present invention provides use of a composition for preparing a medicament for preventing or treating hair loss, the composition comprising: (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

[0050] In an exemplary embodiment of the present invention, the pharmaceutical composition may be administered simultaneously or sequentially with minoxidil, a pharmaceutically acceptable salt thereof, or the like, but is not limited thereto.

[0051] In another exemplary embodiment of the present invention, the composition may be used to promote hair growth or hair regeneration, but is not limited thereto.

[0052] In another exemplary embodiment of the present invention, the aldehyde dehydrogenase 2 activator can enhance the hair loss therapeutic effect of minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof, but is not limited thereto.

[0053] In another exemplary embodiment of the present invention, the aldehyde dehydrogenase 2 activator may be Alda-1 or a pharmaceutically acceptable salt thereof, but is not limited thereto.

[0054] In another exemplary embodiment of the present invention, Alda-1 or a pharmaceutically acceptable salt thereof may be included in a concentration of 0.0001 to 50 mM relative to the total composition, but is not limited thereto.

[0055] In another exemplary embodiment of the present invention, the composition may satisfy one or more properties selected from the group consisting of, but not limited to: (a) promoting the proliferation of hair dermal papilla cells or outer root sheath cells; (b) promoting the growth of hair follicles; (c) inducing the growth phase of hair; and (d) increasing mitochondrial activity.

[0056] In yet another exemplary embodiment of the present invention, the composition may increase the level or activity of one or more proteins selected from the group consisting of, but not limited to, bFGF, FGF-7, IGF-1, and PDGF.

[0057] In yet another exemplary embodiment of the present invention, the composition may reduce oxidative stress of hair dermal papilla cells or outer root sheath cells, but is not limited thereto.

[0058] Another aspect of the present invention provides a pharmaceutical composition for preventing or treating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof as active ingredients.

[0059] In an exemplary embodiment of the present invention, the aldehyde dehydrogenase 2 activator may be Alda-1 or a pharmaceutically acceptable salt thereof, but is not limited thereto.

[0060] In another exemplary embodiment of the present invention, the composition may be in the form of a mixed preparation in which (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof are mixed, but is not limited thereto.

[0061] In yet another exemplary embodiment of the present invention, the composition may be in a form in which (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof are each formulated and administered simultaneously, separately or sequentially, but is not limited thereto.

[0062] Another aspect of the present invention provides a cosmetic composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically (or cosmetically) acceptable salt thereof, or an analog thereof as active ingredients.

[0063] In an exemplary embodiment of the present invention, the composition may be an external preparation in the form of a scalp care agent, soap, hair tonic, shampoo, hair dye, hair mask, hair gel, lotion, conditioner, hair oil, mousse, cream, solid, solution, emulsion, dispersion, micelle, liposome, ointment, perfume, essential oil, patch or spray, but is not limited thereto.

[0064] Another aspect of the present invention provides a quasi-drug composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof as active ingredients.

[0065] Another aspect of the present invention provides a cosmetic composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically (or food) acceptable salt thereof or the like as active ingredients.

[0066] Another aspect of the present invention provides a health functional food composition for preventing or alleviating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically (or food-related) acceptable salt thereof or an analog thereof as active ingredients.

[0067] Another aspect of the present invention provides a method for preventing or alleviating hair loss, the method comprising administering to a subject in need thereof a composition comprising (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof. The method may be a cosmetic method.

[0068] Another aspect of the present invention provides use of a composition for preventing or alleviating hair loss, the composition comprising: (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

[0069] Another aspect of the present invention provides use of a composition for preparing a medicament for preventing or alleviating hair loss, the composition comprising: (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

[0070] Still another aspect of the present invention provides a pharmaceutical composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient for use in combination with a hair loss therapeutic agent.

[0071] Another aspect of the present invention provides use of an aldehyde dehydrogenase 2 activator for preparing a combined preparation with a hair loss therapeutic agent.

[0072] [Beneficial Effects]

[0073] The present invention relates to a composition for preventing, alleviating and / or treating hair loss or gray hair, etc., and is accomplished by confirming that an aldehyde dehydrogenase 2 (ALDH2) activator promotes hair follicle formation and hair growth and has an excellent effect of inhibiting oxidative stress of hair follicles. Specifically, the inventors have confirmed that the ALDH2 activator promotes the proliferation of hair dermal papilla cells and outer root sheath cells, which are key cells in hair follicle formation and hair growth, and promotes cell division in hair follicles, and has confirmed that when a mouse model is treated with an ALDH2 activator, the growth phase of hair growth is induced. In addition, it has been confirmed that treatment with an ALDH2 activator increases the level of hair growth promoting factors in hair dermal papilla cells, etc., and inhibits oxidative stress, which is the cause of hair loss and gray hair. As described above, the ALDH2 activator according to the present invention can effectively promote the formation and growth of hair follicles, and can therefore be used as a preparation for preventing, alleviating and / or treating hair loss and gray hair. In particular, when a mouse model was treated with the ALDH2 activator according to the present invention, the activator showed the same or better effect as the hair loss therapeutic agent minoxidil even at a very small dose, and thus it is expected to have the effect of not only reducing the development cost of the therapeutic agent but also making the therapeutic agent safer in clinical application.

[0074] In addition, the combined treatment of ALDH2 activator and minoxidil showed better hair loss prevention and treatment effects. Therefore, since ALDH2 according to the present invention not only effectively promotes hair growth by itself, but also achieves a synergistic hair loss treatment effect when used in combination with minoxidil, it is expected to be effectively used in the medical, beauty and food fields to prevent, alleviate and treat hair loss. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1a Shown are results of treating hair dermal papilla cells derived from human hair follicles with an ALDH2 activator (Alda-1, the same below) and performing CCK8 analysis to confirm the effect of the ALDH2 activator on the proliferation of hair dermal papilla cells according to an exemplary embodiment of the present invention.

[0076] Figure 1b Shown are the results of treating outer root sheath cells derived from human hair follicles with an ALDH2 activator and performing CCK8 analysis to confirm the effect of ALDH2 activation on outer root sheath cell proliferation.

[0077] Figure 2a and 2b This is a diagram showing the results of a human hair follicle organ culture experiment conducted to confirm the effect of ALDH2 activation on hair growth in hair follicles. Figure 2a shows a hair elongation effect in hair follicles treated with an ALDH2 activator, and Figure 2b Shown are the results of immunofluorescence staining with a Ki-67 antibody to confirm cell proliferation in hair follicles treated with an ALDH2 activator and cultured.

[0078] Figure 3 Shown are the results of treating the mouse model with an ALDH2 activator and comparing the extent of anagen hair growth in each group to confirm the effect of ALDH2 activation on the induction of anagen.

[0079] Figure 4 The results of histological analysis of the extent of anagen hair follicle formation in the mouse model according to ALDH2 activation by hematoxylin and eosin staining are shown.

[0080] Figure 5a Shown are the results of confirming the growth phase induction score of ALDH2 activators in a mouse model.

[0081] Figure 5b Shown are the results of confirming changes in skin thickness caused by an ALDH2 activator in a mouse model.

[0082] Figure 6The results of confirming the protein level of hair growth promoting factor by ELISA assay after treating hair dermal papilla cells and outer root sheath cells derived from human hair follicles with ALDH2 activators are shown to confirm the hair growth promoting mechanism of ALDH2 activators.

[0083] Figure 7 The results of detecting fluorescently labeled DCFDA after treating hair dermal papilla cells with an ALDH2 activator are shown to confirm the oxidative stress suppressive effect of the ALDH2 activator.

[0084] Figure 8a and 8b The results of measuring DCFDA levels after outer root sheath cells were treated with ALDH2 activators are shown ( Figure 8a ) and confirmed the results of ROS clearance ( Figure 8b ) to confirm the oxidative stress inhibitory effect of ALDH2 activators.

[0085] Figure 9a A set of images taken after fluorescent staining of mitochondrial outer membrane protein (VDAC, green) and ALDH2 protein (red) in hair loss patient tissue (blue: DPAI) are shown.

[0086] Figure 9b Comparison of ALDH2 expression levels in telogen and anagen follicles is shown.

[0087] Fig.10a The results of confirming the oxygen consumption efficiency of cells after outer root sheath cells derived from human hair follicles were treated with an ALDH2 activator are shown to confirm changes in mitochondrial activity depending on ALDH2 activity in human hair follicles.

[0088] Figures 10b to 10d Figure 2 shows the basal respiration rate of outer root sheath cells derived from human hair follicles after treatment with ALDH2 activators ( Fig.10b ), maximum respiratory rate( Fig.10c ) and mitochondrial ATP production ( Fig.10d ) results.

[0089] Fig.11 The results of observing the extent of hair growth after applying ALDH2 activators and / or minoxidil on the back of shaved mice (top) and detecting the hair dermal papilla cell marker versican by immunofluorescence staining (bottom) are shown to confirm the effect of combined use of ALDH2 activators and minoxidil on the treatment of alopecia. DETAILED DESCRIPTION

[0090] The present invention relates to a composition for preventing, alleviating and / or treating hair loss or gray hair (or gray hair disease), etc., and is accomplished by confirming that an aldehyde dehydrogenase 2 (ALDH2) activator promotes hair follicle formation and hair growth and has an excellent effect of suppressing oxidative stress of hair follicles.

[0091] In addition, the present invention relates to a combined therapy for preventing, alleviating and / or treating hair loss, and is accomplished by confirming that an aldehyde dehydrogenase 2 (ALDH2) activator not only promotes hair follicle formation and growth but also inhibits oxidative stress in hair follicles, and therefore not only exerts an excellent hair loss therapeutic effect alone, but also exerts a more significant hair loss therapeutic effect when used in combination with minoxidil.

[0092] Specifically, in one example of the present invention, it was confirmed that the proliferation of hair dermal papilla cells and outer root sheath cells derived from human hair follicles was promoted during treatment with the ALDH2 activator Alda-1 (Example 1).

[0093] In another example of the present invention, as a result of treating hair follicles with Alda-1 and culturing the hair follicles by a human hair follicle organ culture test, it was confirmed that hair elongation and cell proliferation in the hair follicles increased (Example 2).

[0094] In another example of the present invention, Alda-1 was applied to a hair loss mouse model, and then the degree of hair growth was compared and histological analysis was performed, confirming that the hair growth phase was induced by ALDH2 activation, thereby increasing hair growth and also increasing skin thickness (Example 3).

[0095] In another example of the present invention, the expression levels of hair growth promoting factors were confirmed by treating hair dermal papilla cells with Alda-1, and it was confirmed that the protein levels of bFGF, FGF-7, IGF-1 and PDGF were increased by ALDH2 activation (Example 4).

[0096] In another example of the present invention, it was confirmed that oxidative stress was reduced in hair dermal papilla cells and outer root sheath cells after treatment with Alda-1 (Example 5).

[0097] In another embodiment of the present invention, it was confirmed that hair follicles in the growth phase have higher levels of ALDH2 and mitochondria, and that ALDH2 and mitochondria exist in the same location, thus confirming that the interaction between ALDH2 and mitochondria is very important for hair growth (Example 6).

[0098] In another example of the present invention, the results of confirming that mitochondrial activity in outer root sheath cells changes with treatment with Alda-1 confirmed that activation of ALDH2 can enhance mitochondrial function, thereby contributing to the induction of the growth phase of hair follicles (Example 7).

[0099] In another embodiment of the present invention, the results of confirming the combined effect of Alda-1 and minoxidil confirmed that the combined administration of the two drugs is more effective in promoting hair growth and hair follicle formation than the treatment with either drug alone (Example 8).

[0100] Therefore, since the activation of ALDH2 not only contributes to hair growth, but also achieves excellent anti-gray hair effects by increasing the level of hair growth promoting factors and reducing oxidative stress to induce hair follicle cell proliferation, the activation of ALDH2 can be used as a therapy for preventing, alleviating and / or treating hair loss and gray hair. In addition, the activation of ALDH2 can exert a more synergistic hair loss treatment effect when used in combination with minoxidil, and therefore can be used together with minoxidil as a combination therapy for preventing, alleviating and / or treating hair loss.

[0101] The present invention will be described in detail below.

[0102] The present invention provides a pharmaceutical composition for preventing or treating hair loss or gray hair, the composition comprising an aldehyde dehydrogenase 2 (ALDH2) activator as an active ingredient. In an exemplary embodiment of the present invention, the pharmaceutical composition (i.e., the aldehyde dehydrogenase 2 activator) can be administered in combination with a hair loss therapeutic agent, but is not limited thereto.

[0103] In the present invention, "hair loss" refers to a state where there is no hair in an area where hair should normally exist, and generally refers to the loss of terminal hair (coarse and black hair) of the scalp. Unlike colorless and thin vellus hair, when terminal hair falls off, it causes aesthetic problems. Clinically, hair loss can be divided into two types: scarring and non-scarring. In scarring alopecia, hair does not regenerate because hair follicles are destroyed, while in non-scarring alopecia, hair regenerates after the affected area disappears because hair follicles are retained. Non-scarring alopecia (where scars are not formed) includes hereditary androgenic alopecia (baldness), alopecia areata, annular tinea pedis caused by fungal infection, telogen effluvium, trichotillomania, hair growth disorder, etc.; scarring alopecia (where scars are formed) includes alopecia caused by lupus, alopecia folliculitis, lichen planus, alopecia caused by burns and trauma, etc. The most common types of alopecia are hereditary androgenic alopecia and alopecia areata, both of which do not leave scars. The most common hair loss includes baldness (male pattern hair loss), female pattern hair loss, alopecia areata, telogen effluvium, etc. Hair loss according to the present invention includes male pattern hair loss and female pattern hair loss.

[0104] Preferably, the hair loss according to the present invention can be selected from the group consisting of: alopecia areata, hereditary androgenic alopecia, telogen effluvium, traumatic alopecia, trichotillomania, compression alopecia, anagen effluvium, pityriasis alopecia, syphilitic alopecia, seborrheic alopecia, symptomatic alopecia and congenital alopecia. In addition to the above diseases, the hair loss according to the present invention can also include any problems caused by the phenomenon of massive hair loss, such as cosmetic problems. Preferably, the hair loss according to the present invention is scalp alopecia.

[0105] The present invention can also be used to prevent and treat gray hair.

[0106] In the present invention, gray hair (gray hair or white hair) refers to hair (especially scalp hair) that has lost its original color and turned gray or white due to aging, stress, etc. Gray hair is a concept that includes not only gray hair that occurs naturally with aging, but also gray hair that appears on the heads of young people who are not aged. In addition, gray hair includes not only the state in which all scalp hair turns gray, but also the state in which part of the scalp hair turns gray, which is a concept that includes not only the graying of the entire hair, but also the graying of part of a single hair (i.e., the appearance of white spots in the hair). Although the molecular mechanism that causes gray hair is still unclear, it is known that the reduction in the function and number of melanocytes is the cause of gray hair. In particular, since the oxidative stress that occurs during the production of melanin in melanocytes can damage melanocytes, it is particularly important to reduce the oxidative stress of hair follicles in order to prevent gray hair.

[0107] White hair includes poliosis. In the present invention, poliosis refers to a disease in which hair loses its color due to a reduction or disappearance of melanin in the hair. Poliosis may occur in adults or children, and may be caused by genetic diseases, autoimmune diseases, hair follicle damage, etc. Poliosis occurs not only on scalp hair, but also on other body hair such as eyelashes and eyebrows. The poliosis described in the present invention is preferably poliosis occurring on scalp hair.

[0108] In the present invention, aldehyde dehydrogenase (ALDH) is a group of enzymes that catalyze aldehyde oxidation. ALDH is involved in a variety of biological processes including exogenous and endogenous aldehyde detoxification, and 19 aldehyde dehydrogenase genes have been identified in the human genome.

[0109] In the present invention, aldehyde dehydrogenase 2 (ALDH2) is an enzyme of aldehyde dehydrogenase subtype 2, encoded by the ALDH2 gene located on chromosome 12. ALDH2 is present in mitochondria and converts acetaldehyde into acetic acid, thereby helping to decompose alcohol absorbed in the body. However, the effect of ALDH2 activation on hair loss or hair regeneration has not been reported. ALDH2 proteins and their encoding genes are well known in the art and can generally be characterized in the protein database Uniprot (Accession No.: P05091).

[0110] The composition according to the present invention can be used to promote hair growth and / or hair regrowth. As used herein, the term "hair regrowth" refers to the growth of new hair, "hair growth" refers to the increase in the length of existing hair (i.e., the growth of hair), and hair growth and "hair care" are used in the same meaning.

[0111] Throughout this specification, hair includes scalp hair (hair on the head) and body hair. Scalp hair refers to hair growing on a person's scalp, and body hair includes hair growing on body parts other than the scalp. Scalp hair and body hair differ in thickness, pore size, etc., but as a representative example, in the case of scalp hair, 1 to 5 hairs grow per pore, while in the case of body hair, 1 hair mostly grows per pore. In addition, although there are differences depending on race, each person has about 80,000 to 120,000 hairs. The thickness of scalp hair also varies from about 17 μm to 180 μm, and is generally characterized as being thicker than body hair, but the average thickness of scalp hair is known to be 80 μm to 150 μm, 90 μm to 150 μm, 100 μm to 150 μm, 110 μm to 150 μm, 120 μm to 150 μm, 130 μm to 150 μm, 80 μm to 140 μm, or 90 μm to 130 μm. Hair grows at different speeds, depending on the area in which it grows, but for example, eyebrows, pubic hair, etc. grow about 0.05 to 0.2 mm per day, while scalp hair grows about 0.3 to 0.5 mm per day and grows 1 cm or more per month. That is, scalp hair is characterized by growing faster than other body hair. Preferably, the composition according to the present invention is used to promote hair growth and / or hair regeneration.

[0112] In the present invention, an ALDH2 activator refers to a substance that can promote hair follicle growth, hair growth and / or hair regeneration by enhancing the expression or activity of ALDH2 protein. In addition, ALDH2 activators also include substances that can prevent or alleviate gray hair by enhancing the expression or activity of ALDH2 protein. Although not limited to a specific type, examples of ALDH2 activators include expression vectors containing ALDH2 encoding genes, ALDH2 agonists, ALDH2 functional activators, and the like.

[0113] In the present invention, the expression of ALDH2 protein ultimately refers to the production of ALDH2 protein, and enhancing the expression of ALDH2 protein is intended to include increasing the mRNA expression at the transcription stage of the ALDH2 coding gene and increasing the translation of mRNA. In the present invention, the increase in mRNA expression may involve activating a mechanism of action that can increase the transcription of the ALDH2 gene with a higher-order mechanism of action of the ALDH2 coding gene, or conversely, inhibiting a higher-order mechanism of action that can inhibit the transcription of the ALDH2 gene. Further, the present invention includes all concepts that can directly or indirectly promote the expression of ALDH2, such as demethylation of the promoter region of the ALDH2 gene or histone modifications associated with the expression of the ALDH2 gene. In the present invention, increasing the translation of ALDH2 mRNA may include all mechanisms that can enhance the translation of the produced ALDH2 mRNA, and may be, for example, inhibiting the expression or activity of miRNAs that prevent the translation of ALDH2 mRNA, or increasing the activity of enzymes associated with the translation of ALDH2 mRNA, but is not limited thereto.

[0114] In addition, in the present invention, "ALDH2 protein activity" refers to the activity of ALDH2 protein produced by the translation process or the activity of ALDH2 protein already produced and present in the cell, and "increasing the activity of ALDH2 protein" includes increasing the activity of ALDH2 protein through processes such as post-translational modification or through the activity / inactivity of proteins interacting therewith.

[0115] In the present invention, the aldehyde dehydrogenase 2 activator may include but is not limited to substances capable of enhancing the expression or activity of aldehyde dehydrogenase 2 protein, but may be preferably selected from the group consisting of Alda-1, AD-9308, compound I-6, and pharmaceutically acceptable salts thereof.

[0116] In the present invention, the aldehyde dehydrogenase 2 activator may preferably be Alda-1. Alda-1 is a compound that acts as an ALDH2 agonist and can penetrate the cell membrane to activate the ALDH2 protein. Although it is known that Alda-1 can reduce oxidative stress in hepatocytes and the like, there has been no report on the effect of Alda-1 on hair follicles or hair growth. Through specific experiments using Alda-1, the inventors have newly discovered that Alda-1 can promote hair growth by activating ALDH2, thereby being used to treat hair loss. Minoxidil is a potassium ion channel activator that promotes hair growth by hyperpolarizing the cell membrane and dilating blood vessels in the hair follicles to increase blood flow, but due to its strong vasodilating properties, excessive use of minoxidil may instead have the risk of inducing fluid retention or edema formation. On the contrary, it has been confirmed that Alda-1 according to the present invention can relieve cell stress by activating ALDH2 to remove cytotoxic aldehydes, and in particular can inhibit oxidative stress in hair follicle cells, which is one of the main causes of hair loss. In particular, in experiments using a mouse model of hair loss, the inventors confirmed that Alda-1 exhibited the same or better therapeutic effect for hair loss even when administered at a lower dose than minoxidil, and that the combined use of the two drugs was more effective in inducing hair growth than the use of these drugs alone. That is, since Alda-1 can achieve an excellent hair growth promoting effect even at a low dose, it can not only significantly reduce the risk of side effects caused by excessive use of minoxidil, but also exhibit a synergistic effect in treating hair loss when used in combination with minoxidil. In addition, it has been confirmed that Alda-1 can enhance mitochondrial function in hair follicles and significantly reduce oxidative stress in hair follicles, so Alda-1 can also be used to prevent, alleviate and treat gray hair or white hair disease caused by oxidative stress.

[0117] Alda-1 according to the present invention may be referred to as N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide. Preferably, Alda-1 according to the present invention may have a structure of the following Chemical Formula 1, but is not limited thereto.

[0118] [Chemical formula 1]

[0119]

[0120] In the present invention, AD-9308 is a water-soluble ALDH2 activator, which is a more effective ALDH2 activator than the prototype Alda-1. Recently, it has been reported that AD-9308 can effectively relieve myocardial fibrosis, inflammation, etc., and can treat cardiac dysfunction, but the efficacy of AD-9308 in treating hair loss is still unclear. For detailed information on the chemical structure and properties of AD-9308, please refer to the literature [Antioxidants (Basel). 2021Mar 13; 10(3): 450.] and U.S. Patent No. 9,879,036B2.

[0121] In the present invention, compound I-6 refers to compound I-6 disclosed in the document [Journal of Saudi Chemical Society Volume 23, Issue 3, March 2019, Pages 255-262]. Compound I-6 is a compound prepared by modifying Alda-1, and is an ALDH2 activator with higher water solubility and higher ALDH2 activation effect. Specific information such as chemical structure and properties of compound I-6 can be found in the above document.

[0122] In the present invention, the hair loss therapeutic agent refers to a substance that can directly or indirectly play a preventive or therapeutic role in hair loss by promoting the formation and growth of hair follicles, inducing the growth phase, relieving hair follicle stress, etc. It is sufficient for the hair loss therapeutic agent to play a preventive or therapeutic effect on hair loss by promoting hair regeneration or hair growth, and is not limited to a specific type, but can be preferably selected from minoxidil, finasteride, dutasteride, pharmaceutically acceptable salts thereof, analogs thereof, etc. In a preferred embodiment, the hair loss therapeutic agent is minoxidil or a pharmaceutically acceptable salt thereof.

[0123] Minoxidil, also known as Rogaine, is a vasodilator used to treat hair loss, and its IUPAC ID is 6-piperidin-1-ylpyrimidine-2,4-diamine 3-oxide. Since topical application of minoxidil increases the blood and nutrient supply to the hair follicles, it can strengthen existing hair and promote its growth. Although the molecular mechanism by which minoxidil promotes hair growth has not been precisely clarified, it is known that minoxidil induces hair growth by reversing the miniaturization of hair follicles, increasing blood flow around the hair follicles, stimulating the hair follicles to enter the growth phase, and prolonging the growth phase of the hair follicles. However, it is known that when administered in high doses, minoxidil may cause side effects such as rash, inflammation, itching, weight gain, edema, and angina. Therefore, the purpose of the present invention is to use a combination of an ALDH2 activator and minoxidil to reduce the risk of minoxidil side effects and provide better hair loss treatment effects. In particular, compared with the effect of preventing or treating hair loss exhibited by using a standard amount of minoxidil, the present invention can show the same or higher level of hair loss prevention, hair growth and hair regeneration promotion effect at a relatively low concentration of minoxidil by using a combination of an ALDH2 activator and minoxidil. Throughout this specification, the concept of "minoxidil" includes not only minoxidil itself, but also its salts, its analogs, etc.

[0124] In the present invention, minoxidil can be 0.1-10 (w / v)%, 0.1-8 (w / v)%, 0.1-6 (w / v)%, 0.1-5 (w / v)%, 0.1-3 (w / v)%, 1-10 (w / v)%, 1-8 (w / v)%, 1-6 (w / v)%, 1-5 (w / v)%, 1-3 (w / v)% or 2-5 (w / v)% minoxidil. Alternatively, minoxidil of the present invention can be 2 (w / v)%, 3 (w / v)% or 5 (w / v)% minoxidil. In general, it is known that 5% or more minoxidil is particularly suitable for male use, and it is known that lower concentrations such as 1-3% minoxidil can be used by both men and women. Minoxidil can be dissolved in water, distilled water, deionized water, ultrapure water or DMSO.

[0125] In the present invention, the ALDH2 activator includes not only the ALDH2 activator itself, but also its pharmaceutically acceptable salts, analogs, derivatives, etc. For example, Alda-1 includes not only Alda-1 itself, but also its pharmaceutically acceptable salts, analogs, derivatives, etc. The hair loss therapeutic agent of the present invention includes not only the hair loss therapeutic agent itself, but also its pharmaceutically acceptable salts, analogs, derivatives, etc. For example, minoxidil is a concept that includes not only minoxidil itself, but also its pharmaceutically acceptable salts, analogs, derivatives, etc.

[0126] In the present invention, the term "pharmaceutically acceptable salt" includes salts derived from pharmaceutically acceptable inorganic acids, organic acids or bases. Further, derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrides, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable complexes, etc.

[0127] Alternatively, as used herein, the term "pharmaceutically acceptable" refers to compounds or compositions that are suitable for contact with the tissues of subjects (e.g., humans) and are within the scope of sound medical judgment because the benefit / risk ratio is reasonable, without excessive toxicity, irritation, allergic response, or other problems or complications.

[0128] The example of suitable acid comprises hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, p-toluenesulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, gluconic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid etc.Acid addition salt can be prepared by typical method, for example, compound is dissolved in the aqueous solution of excessive acid, and uses organic solvent miscible with water such as methanol, ethanol, acetone or acetonitrile to make salt precipitation.In addition, acid addition salt can be by heating equimolar compound and acid or alcohol in water, then evaporate its mixture so that mixture is dried, or the salt of suction filtration precipitation is prepared.

[0129] Salts derived from suitable bases may include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, ammonium, etc., but are not limited thereto. Alkali metal or alkaline earth metal salts may be obtained, for example, by dissolving the compound in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, evaporating the filtrate, and drying the resulting product. In this case, sodium, potassium or calcium salts are particularly suitable for preparation as metal salts in pharmaceutical practice, and corresponding silver salts may also be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

[0130] The scope of the compounds of the present invention includes not only pharmaceutically acceptable salts but also all isomers, hydrates and solvates which can be prepared by typical methods.

[0131] The ALDH2 activator according to the present invention can be administered in combination with a hair loss therapeutic agent. The term "co-administration" used herein can be achieved by a method of administering the individual components of the treatment regimen simultaneously, sequentially or separately. The effect of the combination therapy is obtained by administering two or more drugs simultaneously or sequentially or by alternating their administration at regular or irregular intervals, and the combination therapy is not limited thereto, but can be defined as providing a synergistic effect while having a better therapeutic effect compared to the therapeutic effect obtained by administering one or another component of the combination therapy at a typical dose, such as measured by the degree of response, the speed of response, the time to disease progression or the survival period. For example, the ALDH2 activator of the present invention, when administered in combination with minoxidil, can enhance the hair loss therapeutic effect of minoxidil or reduce the side effects caused by minoxidil. Administration (treatment) is a concept including all methods such as injection, oral administration, inhalation, spraying, and smearing.

[0132] In the present invention, the ALDH2 activator can be administered simultaneously, separately or sequentially with the hair loss therapeutic agent (e.g., minoxidil), and even if the ALDH2 activator and the hair loss therapeutic agent are administered sequentially, the administration order is not limited, but the administration regimen can be appropriately adjusted according to the type of hair loss therapeutic agent, patient condition, patient gender, age, etc.

[0133] The present invention also provides a pharmaceutical composition for preventing or treating hair loss, the composition comprising an aldehyde dehydrogenase 2 activator and minoxidil as active ingredients.

[0134] The composition may be in the form of a mixture of the ALDH2 activator and minoxidil, or in the form of simultaneous administration of the ALDH2 activator and minoxidil. For example, the ALDH2 activator and minoxidil may be a single preparation prepared by mixing with pharmaceutically acceptable excipients, diluents, carriers, etc. In this case, the ALDH2 activator and minoxidil may each include various ingredients within the corresponding drug class. In addition, the single preparation may be administered together with a separate preparation including another therapeutic agent, the latter being a separate preparation different from the single preparation.

[0135] Alternatively, the composition may be in the form of an ALDH2 activator and minoxidil each formulated and administered simultaneously, separately or sequentially. In this case, the composition may be a pharmaceutical composition for co-administration administered simultaneously or sequentially, comprising a first pharmaceutical composition comprising a pharmaceutically effective amount of an ALDH2 activator as an active ingredient; and a second pharmaceutical composition comprising a pharmaceutically effective amount of minoxidil as an active ingredient. In other words, the ALDH2 activator and minoxidil may be provided as separate pharmaceutical preparations, each of which is administered simultaneously or at different times. The ALDH2 activator and minoxidil may be in the same preparation or in different preparations, and may be administered independently according to the preparation. In this case, in the case of sequential administration, the order of administration is not limited, and the administration regimen may be appropriately adjusted according to the patient's condition, etc.

[0136] For example, when the pharmaceutical composition is a pharmaceutical composition for co-administration to be administered sequentially, the ALDH2 activator (first component) may be administered first, and then minoxidil (second component) may be administered, or they may be administered in the reverse order.

[0137] The content of the ALDH2 activator (e.g., Alda-1), the hair loss therapeutic agent (e.g., minoxidil), and / or a pharmaceutically acceptable salt thereof in the composition of the present invention can be appropriately adjusted according to the symptoms of the disease, the degree of progression of the symptoms, the condition of the patient, etc., and can be, for example, 0.0001 to 99.9% by weight or 0.001 to 50% by weight based on the total weight of the composition, but is not limited thereto. The content ratio is a value based on the dry amount after removing the solvent.

[0138] In one embodiment of the present invention, an ALDH2 activator (e.g., Alda-1) or a pharmaceutically acceptable salt thereof may be included at a concentration of 0.0001 to 50 mM relative to the entire composition, but is not limited thereto. More specifically, Alda-1 or a pharmaceutically acceptable salt thereof according to the present invention may be included in the composition at the following concentrations relative to the entire composition: 0.0001 to 50 mM, 0.0001 to 40 mM, 0.0001 to 30 mM, 0.0001 to 20 mM, 0.0001 to 10 mM, 0.0001 to 9 mM, 0.0001 to 8 mM, 0.0001 to 7 mM, 0.0001 to 6 mM, 0.0001 to 5 mM, 0.0001 to 4 1 to 30 mM, 1 to 20 mM, 1 to 15 mM, 1 to 10 mM, 1 to 9 mM, 1 to 8 mM, 1 to 7 mM, 1 to 6 mM, or 1 to 5 mM, but are not limited thereto.

[0139] In other words, the composition of the present invention may contain an ALDH2 activator or a pharmaceutically acceptable salt thereof in an amount such that, when administered or applied once to a subject in need thereof, the ALDH2 activator or a pharmaceutically acceptable salt thereof is administered (applied) at a concentration of 0.0001 to 50 mM relative to the entire composition (or solvent). That is, in the present invention, the ALDH2 activator or a pharmaceutically acceptable salt thereof may be administered (to a subject in need thereof) at a concentration of 0.0001 to 50 mM relative to the entire composition (or solvent).

[0140] The composition according to the present invention may be in the form of a liquid preparation. When the composition of the present invention is a liquid preparation, it may contain an ALDH2 activator or a pharmaceutically acceptable salt thereof at a concentration of 0.0001 to 50 mM relative to the entire liquid preparation. In addition, when applied (smeared) once, the liquid preparation may be administered at a dose of 10 μL to 20 mL, 10 μL to 10 mL, 10 μL to 5 mL, 10 μL to 1 mL, 10 μL to 900 μL, 10 μL to 800 μL, 10 μL to 700 μl, 10 μL to 500 μl, 10 μl to 400 μL, 10 μl to 300 μL, 10 μL to 200 μL, or 10 μl to 100 μl, but is not limited thereto.

[0141] In one example of the present invention, a hair loss therapeutic agent (e.g., minoxidil) or a pharmaceutically acceptable salt thereof may be included in a concentration of 0.0001 to 10 (w / v)% relative to the entire composition, but is not limited thereto. More specifically, the hair loss therapeutic agent or a pharmaceutically acceptable salt thereof according to the present invention may be included in the composition at the following concentrations: 0.0001 to 10 (w / v)%, 0.0001 to 5 (w / v)%, 0.0001 to 3 (w / v)%, 0.0001 to 2 (w / v)%, 0.0001 to 1 (w / v)%, 0.0005 to 5 (w / v)%, 0.0005 to 3 (w / v)%, 0.0005 to 2 (w / v)%, 0.0005 to 1 (w / v)%, 0. 0.01 to 5 (w / v)%, 0.001 to 3 (w / v)%, 0.001 to 2 (w / v)%, 0.001 to 1 (w / v)%, 0.005 to 5 (w / v)%, 0.005 to 3 (w / v)%, 0.005 to 2 (w / v)%, 0.01 to 5 (w / v)%, 0.01 to 3 (w / v)%, 0.01 to 2 (w / v)%, 0.05 to 2 (w / v)%, 0.1 to 2 (w / v)%, or 0.1 to 1 (w / v)%, but is not limited to these.

[0142] Alternatively, the composition of the present invention may contain a hair loss therapeutic agent or a pharmaceutically acceptable salt thereof in an amount such that when the composition is applied or smeared once to a subject in need thereof, the hair loss therapeutic agent or a pharmaceutically acceptable salt thereof is applied (smeared) at a concentration of 0.0001 to 10 (w / v)% relative to the entire composition (or solvent). That is, in the present invention, the hair loss therapeutic agent or a pharmaceutically acceptable salt thereof may be applied (to a subject in need thereof) at a concentration of 0.0001 to 10 (w / v)% relative to the entire composition (or solvent).

[0143] As described above, the composition according to the present invention may be in the form of a liquid preparation, and when the composition of the present invention is a liquid preparation, it may contain a hair loss therapeutic agent (e.g., minoxidil) or a pharmaceutically acceptable salt thereof at a concentration of, but not limited to, 0.0001 to 10 (w / v)% relative to the entire liquid preparation. In addition, when applied (smeared) once, the liquid preparation may be applied in the following doses: 10 μL to 20 mL, 10 μL to 10 mL, 10 μL to 5 mL, 10 μL to 1 mL, 10 μL to 900 μL, 10 μL to 800 μL, 10 μL to 700 μl, 10 μL to 500 μl, 10 μl to 400 μL, 10 μl to 300 μL, 10 μL to 200 μL, or 10 μl to 100 μl, but not limited thereto.

[0144] The ALDH2 activator of the present invention and the hair loss therapeutic agent (e.g., minoxidil, its analogs or pharmaceutically acceptable salts thereof) can be used in combination at a weight ratio of 1:0.01 to 100, but is not limited thereto. In particular, the ALDH2 activator and minoxidil can be used in combination at the following weight ratios: 1:0.01 to 100, 1:0.01 to 80, 1:0.01 to 60, 1:0.01 to 50, 1:0.01 to 40, 1:0.01 to 30, 1:0.01 to 20, 1:0.01 to 10, 1:1 to 100, 1:1 to 80, 1:1 to 50, 1:1-20, 1:1-10, 1:10-100, 1:10-50, 1:10-40, 1:10-30, 1:20-100, 1:20-80, 1:20-50, 1:20-40, 1:30-100, 1:30-80, 1:30-50, 1:30-40, 1:35-40, or 1:37, but is not limited thereto.

[0145] In addition, when the ALDH2 activator and the hair loss therapeutic agent of the present invention are used in combination in the form of a liquid preparation, the respective liquid preparations can be mixed together and used for combined treatment in the form of a mixed preparation. The mixed preparation can be prepared, for example, by mixing a liquid preparation containing an ALDH2 activator at a concentration of 0.0001 to 50 mM with a liquid preparation containing a hair loss therapeutic agent at a concentration of 0.0001 to 10 (w / v)%. Here, the liquid preparation containing the ALDH2 activator and the liquid preparation containing the hair loss therapeutic agent can be mixed in a volume ratio of 1:0.1 to 10, 1:0.1 to 5, 1:0.1 to 2, 1:0.1 to 1.5, 1:0.1 to 1, 1:0.5 to 5, 1:0.5 to 2, 1:0.5 to 1.5 or 1:1, but is not limited thereto. Further, the mixed preparation can be administered in a dose of 10 μL to 20 mL, 10 μL to 10 mL, 10 μL to 5 mL, 10 μL to 1 mL, 10 μL to 900 μL, 10 μL to 800 μL, 10 μL to 700 μl, 10 μL to 500 μl, 10 μl to 400 μL, 10 μl to 300 μL, 10 μL to 200 μL or 10 μl to 100 μl when administered (applied or treated) once, but is not limited thereto.

[0146] When the pharmaceutical composition according to the present invention is applied to the skin of a subject in need thereof, the therapeutic concentration, therapeutic dose, etc. of the above-mentioned ALDH2 activator and hair loss therapeutic agent may be particularly suitable. However, the administration form of the pharmaceutical composition according to the present invention is not limited to a specific type, and those skilled in the art can select appropriate volumes, concentrations, mixing ratios, etc. based on the common technical knowledge in the art, taking into account the drug treatment route, treatment method, type of drug used in combination, condition of the subject, etc.

[0147] Preferably, the composition according to the present invention can satisfy one or more properties selected from but not limited to the group consisting of: (a) promoting the proliferation (cell division) of hair dermal papilla cells and / or outer root sheath cells; (b) promoting the growth of hair follicles (i.e. promoting the growth or cell division of cells in hair follicles); (c) inducing the growth phase of hair; and (d) increasing mitochondrial activity.

[0148] Preferably, the composition of the present invention can increase the level or activity of one or more proteins selected from the group consisting of basic fibroblast growth factor (bFGF), keratinocyte growth factor (FGF-7), insulin-like growth factor 1 (IGF-1) and platelet-derived growth factor (PDGF), but is not limited thereto.

[0149] Preferably, the composition according to the present invention can reduce oxidative stress in hair dermal papilla cells or outer root sheath cells, but is not limited thereto.

[0150] The pharmaceutical composition of the present invention may also include suitable carriers, adjuvants and diluents, which are commonly used to prepare pharmaceutical compositions. The adjuvant may be, for example, one or more selected from the group consisting of diluents, binders, disintegrants, lubricants, adsorbents, wetting agents, film coating materials and controlled release additives.

[0151] The pharmaceutical composition according to the present invention can be formulated into powders, granules, sustained-release granules, enteric-coated granules, liquids, eyewashes, elixirs, emulsions, suspensions, spirits, lozenges, aromatic waters, lemonades, tablets, sustained-release tablets, enteric-coated tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric-coated capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, infusions, external preparations such as plasters, lotions, pastes, sprays, inhalants, patches, sterile injection solutions or aerosols, and the external preparations can have dosage forms such as creams, gels, patches, sprays, ointments, plasters, lotions, liniments, pastes and cataplasms.

[0152] Examples of carriers, excipients or diluents that may be included in the composition according to the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate and mineral oil.

[0153] When preparing a pharmaceutical composition, a generally used diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant and a surfactant are used to prepare the pharmaceutical composition.

[0154] As additives for tablets, powders, granules, capsules, pills, and lozenges according to the present invention, auxiliary materials such as corn starch, potato starch, wheat starch, lactose, white sugar, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium hydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, purified lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica, hydroxypropyl starch, hydroxypropyl methylcellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate and Primojel; and binders such as gelatin, gum arabic, ethanol, agar powder, cellulose acetate phthalate, carboxymethyl cellulose, carboxymethyl cellulose calcium, glucose, purified water, sodium caseinate, glycerin, stearic acid, sodium carboxymethyl cellulose, sodium methyl cellulose, methyl cellulose, microcrystalline cellulose, dextrin, hydroxycellulose, hydroxypropyl starch, hydroxymethyl cellulose, purified shellac, starch, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl alcohol and polyvinyl pyrrolidone; and disintegrants such as hydroxypropyl methyl cellulose, corn starch, agar powder, methyl cellulose, bentonite, hydroxypropyl starch, carboxymethyl cellulose sodium, sodium alginate, carboxymethylcellulose calcium, calcium citrate, sodium lauryl sulfate, silicic anhydride, 1-hydroxypropyl cellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinyl pyrrolidone, calcium phosphate, gelling starch, gum arabic, pullulan, pectin, sodium polyphosphate, ethyl cellulose, white sugar, magnesium aluminum silicate, D-sorbitol solution and light anhydrous silicic acid; and lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium powder, kaolin, petrolatum, sodium stearate, cocoa butter, sodium salicylate, magnesium salicylate, polyethylene glycol (PEG) 4000, PEG 6000, liquid paraffin, hydrogenated soybean oil (Lubriwax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, Macrogol, synthetic aluminum silicate, silicic anhydride, higher fatty acids, higher alcohols, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine and light anhydrous silicic acid.

[0155] As additives for the liquid preparation according to the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitan fatty acid esters (Tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, lanolin esters, acetic acid, hydrochloric acid, ammonia water, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamin, polyvinyl pyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, etc. can be used.

[0156] In the syrup according to the present invention, a solution of sucrose, other sugars or sweeteners or the like may be used, and if necessary, flavorings, colorants, preservatives, stabilizers, suspending agents, emulsifiers, thickeners or the like may be used.

[0157] Purified water can be used for the emulsion according to the present invention, and an emulsifier, a preservative, a stabilizer, a flavor, etc. can be used as necessary.

[0158] In the suspension according to the present invention, suspending agents such as gum arabic, gum tragacanth, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropyl methylcellulose (HPMC), HPMC1828, HPMC 2906 and HPMC 2910 may be used, and surfactants, preservatives, colorants and flavors may be used as necessary.

[0159] The injection according to the present invention may contain a solvent, such as distilled water for injection, 0.9% sodium chloride injection, Ringer's injection, glucose injection, glucose + sodium chloride injection, PEG, lactated Ringer's injection, ethanol, propylene glycol, non-volatile oils such as sesame oil, cottonseed oil, peanut oil, corn oil, ethyl oleate, isopropyl myristate or benzene benzoate; a solubilizing aid, such as sodium benzoate, sodium salicylate, sodium acetate, urea, ethyl carbamate, monoethylacetamide, phenbutazoline, propylene glycol, Tweens, nicotinamide, hexamethylenetetramine or dimethylacetamide; a buffer, such as a weak acid or a salt thereof (acetic acid or sodium acetate), a weak base or a salt thereof ( ammonia or ammonium acetate), an organic compound, protein, albumin, peptone or gum; an isotonic agent such as sodium chloride; a stabilizer such as sodium bisulfite (NaHSO3), carbon dioxide gas, sodium pyrosulfite (Na2S2O5), sodium sulfite (Na2SO3), nitrogen (N2) or ethylenediaminetetraacetic acid; a sulfating agent such as 0.1% sodium hydrosulfide, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetic acid or sodium acetone bisulfite; an analgesic such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose or calcium gluconate; and a suspending agent such as sodium carboxymethylcellulose, sodium alginate, Tween 80 or aluminum monostearate.

[0160] Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and are prepared by mixing at least one auxiliary material such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. with the extract. In addition, in addition to simple auxiliary materials, lubricants such as magnesium stearate and talc are also used.

[0161] Liquid preparations for oral administration correspond to suspensions, internal liquids, emulsions, syrups, etc., and liquid preparations can also include various adjuvants, such as wetting agents, sweeteners, spices, preservatives, etc., in addition to the commonly used simple diluents of water and liquid paraffin. Examples of preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. can be used.

[0162] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio suitable for medical treatment, and the effective dose level can be determined based on factors including the patient's disease type, the severity of the disease, the activity of the drug, sensitivity to the drug, the time of administration, the route of administration, the excretion rate, the treatment period, the drugs used simultaneously, and other factors known in the medical field. For example, the composition according to the present invention can be administered (applied) to a subject in need 1 to 5 times, 1 to 3 times, 1 to 2 times, or 1 time a day. In this case, the dosage can be adjusted according to the severity of the lesions associated with hair loss.

[0163] The pharmaceutical composition according to the present invention can be used as a single therapeutic agent or in combination with other therapeutic agents, can be used sequentially or simultaneously with the therapeutic agents in the related art, and can be used in a single dose or multiple doses. Taking all of the above factors into consideration, it is very important to use the composition in the minimum amount that can achieve the maximum effect without any side effects, and this amount can be easily determined by a person of ordinary skill in the art to which the present invention belongs.

[0164] In addition, the pharmaceutical composition according to the present invention can be administered to a subject in need 1 to 10 times, 1 to 5 times, 1 to 3 times, or 1 to 2 times a day, and can be administered at intervals of 1 to 10 days, 1 to 5 days, 1 to 3 days, or every day, but is not limited thereto.

[0165] The pharmaceutical composition of the present invention can be administered to a subject in need by various routes. All methods of administration can be considered, but the pharmaceutical composition can be administered by, for example, oral administration, subcutaneous injection, peritoneal administration, intravenous injection, intramuscular injection, paravertebral space (intradural) injection, sublingual administration, buccal administration, rectal insertion, vaginal injection, ocular administration, ear administration, nasal administration, inhalation, oral or nasal spray, skin administration, transdermal administration, etc.

[0166] The pharmaceutical composition of the present invention is determined by the type of drug as an active ingredient and various related factors such as the disease to be treated, the administration route, the age, sex and weight of the patient and the severity of the disease.

[0167] As used herein, "subject" refers to a subject in need of treatment for a disease, and more specifically, refers to a mammal, such as a human or non-human primate, mouse, rat, dog, cat, horse, and cow.

[0168] As used herein, "administering" means providing a predetermined composition of the present invention to a subject in need thereof by any suitable method.

[0169] As used herein, "prevention" refers to all actions that inhibit or delay the onset of the target disease, while "treatment" refers to all actions that improve or beneficially change the target disease and the metabolic abnormalities caused by it by administering the pharmaceutical composition according to the present invention, and "relief" refers to all actions that reduce the target disease and its related parameters (such as the severity of symptoms) by administering the composition according to the present invention.

[0170] In addition, the present invention provides a cosmetic composition for preventing or alleviating hair loss or gray hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient. The cosmetic composition can be administered in combination with a hair loss therapeutic agent. In addition, the present invention provides a cosmetic composition for preventing or alleviating hair loss, the composition comprising an aldehyde dehydrogenase 2 activator and a hair loss therapeutic agent as active ingredients.

[0171] Preferably, the ALDH2 activator is Alda-1, an analog thereof, or a cosmetically acceptable salt thereof, and the hair loss therapeutic agent may be minoxidil, an analog thereof, or a cosmetically acceptable salt thereof.

[0172] Here, prevention or alleviation of gray hair means suppressing the fading of hair to maintain its original color, and this effect can be achieved particularly by maintaining the function and number of melanocytes.

[0173] The formulation of the cosmetic composition according to the present invention may be in the form of a body lotion, a skin softener, a toner, a lotion, an emulsion, a milk emulsion, a moisturizing emulsion, a nourishing emulsion, a massage cream, a nourishing cream, a spray, a moisturizing cream, a hand cream, a hand lotion, a foundation, an essence, a nourishing essence, a mask, a soap, a cleansing foam, a cleansing emulsion, a cleansing cream, a cleansing oil, a cleansing paste, a body lotion or a body cleanser.

[0174] Preferably, the composition can be an external preparation in the form of a scalp care agent, soap, hair tonic, shampoo, hair dye, hair mask, hair gel, lotion, conditioner, hair oil, mousse, cream, solid, solution, emulsion, dispersion, micelle, liposome, ointment, perfume, essential oil, patch or spray.

[0175] The cosmetic composition of the present invention may further comprise a composition selected from the group consisting of water-soluble vitamins, fat-soluble vitamins, polymer peptides, high molecular weight polysaccharides and sphingolipids.

[0176] If necessary, other ingredients generally added to cosmetics may also be blended with the cosmetic composition of the present invention together with the essential ingredients.

[0177] Examples of other blending ingredients that may be added include oil components, wetting agents, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, circulation accelerators, coolants, antiperspirants, purified water, etc.

[0178] In addition, blending components that can be added are not limited to the above components, and any component may be blended within a range that does not impair the object and effect of the present invention, but may be blended at 0.01 to 5 wt % or 0.01 to 3 wt % based on the total weight.

[0179] When the preparation of the present invention is a lotion, paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc, zinc oxide and the like can be used as carrier components.

[0180] When the preparation of the present invention is a powder or a spray, lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component, and in particular, when the preparation is a spray, a propellant such as chlorofluorocarbons, propane / butane or dimethyl ether can be contained in the preparation.

[0181] When the preparation of the present invention is a solution or emulsion, a solvent, a solubilizer or an emulsifier is used as a carrier component, examples of which include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan fatty acid esters.

[0182] When the preparation of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum hydroxide, bentonite, agar, tragacanth gum, etc. can be used as a carrier component.

[0183] When the preparation of the present invention is a surfactant-containing cleanser, fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazoline derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamide betaines, fatty alcohols, glycerol fatty acid esters, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glycerol fatty acid esters, etc. can be used as carrier components.

[0184] In addition, the composition according to the present invention can be provided in the form of a quasi-drug composition. In the present invention, "quasi-drug" refers to a product used to treat, alleviate, control or prevent a disease in humans or animals, and a product that has only a slight effect on the human body or does not directly act on the human body.

[0185] The quasi-drug composition of the present invention may contain a pharmaceutically acceptable carrier, excipient or diluent, in addition to the above-mentioned components, if necessary. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not affect the effect of the present invention, and may include, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, flavors, preservatives, etc.

[0186] Representative examples of acceptable carriers, excipients or diluents for the quasi-drug composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, gum arabic rubber, alginate, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable esters, Witepsol, Macrogol, Tween 61, cocoa butter, trilaurin and the like.

[0187] When the composition of the present invention is provided as an external preparation, the composition may be in the form of a liquid, an ointment, a patch, a gel, a cream or a spray, but is not limited thereto. According to an exemplary embodiment of the present invention, the quasi-drug of the present invention may include oral care products, including toothpaste, mouthwash and oral spray, ointment, mask, paste, patch, transdermal agent, etc. The preparation method, dosage, method of use, ingredients, etc. of the quasi-drug may be appropriately selected from typical techniques known in the art.

[0188] In addition, the present invention provides a food composition for preventing or alleviating hair loss or gray hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient. The composition can be administered in combination with a hair loss therapeutic agent. In addition, the present invention provides a food composition for preventing or alleviating hair loss, the composition comprising an ALDH2 activator and a hair loss therapeutic agent as active ingredients. Preferably, the hair loss therapeutic agent is minoxidil, an analog thereof, or a food-acceptable salt thereof.

[0189] The aldehyde dehydrogenase 2 activator may preferably be Alda-1 or a food-acceptable salt thereof. In the present invention, the food-acceptable salt includes salts derived from food-acceptable organic acids, inorganic acids or bases.

[0190] When the ALDH2 activator of the present invention is used as a food additive, the ALDH2 activator can be added as it is or used together with another food or other food ingredients, and can be used appropriately according to typical methods. The amount of the active ingredient mixed can be appropriately determined according to the purpose of use (prevention, health care or treatment). In general, when preparing food or beverages, the ALDH2 activator of the present invention can be added in an amount of 15% by weight or less, or 10% or less based on the raw material. However, in the case of long-term intake for health and hygiene purposes or for the purpose of controlling health, the amount may be lower than the above range, and the active ingredient may be used in an amount higher than the above range because there is no problem in terms of safety.

[0191] There is no particular restriction on the type of food. Examples of foods to which the material can be added include meat, sausages, bread, chocolate, candy, snacks, sweets, pizza, instant noodles, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, etc., and include all health functional foods in a typical sense.

[0192] Health drink composition according to the present invention can comprise various flavoring agents or natural carbohydrates etc. as additional ingredients like typical beverages.Above-mentioned natural carbohydrates can be monosaccharides, such as glucose and fructose, disaccharides, such as maltose and sucrose, polysaccharides, such as dextrin and cyclodextrin, and sugar alcohols, such as xylitol, sorbitol and erythritol.As sweetener, natural sweeteners can be used, such as thaumatin and stevia extract, synthetic sweeteners, such as saccharin or aspartame etc.The ratio of natural carbohydrates is generally about 0.01 to 0.20g per 100ml of the present composition, or about 0.04 to 0.10g.

[0193] In addition to the above ingredients, the composition of the present invention may also include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerine, alcohol, the carbonating agent used in carbonated beverages, etc. In addition, the composition of the present invention may also include the pulp used to prepare natural fruit juice, fruit juice beverages and vegetable beverages. These ingredients may be used alone or in combination. The ratio of these additives is not very important, but is generally selected from the range of 0.01 to 0.20 weight parts in every 100 weight parts of the composition of the present invention.

[0194] As used herein, health functional food is the same term as food for special health use (FoSHU), which refers to food with high medical and medicinal effects, which is processed to effectively play a biological regulation function in addition to nutritional supply. The food can be made into various forms such as tablets, capsules, powders, granules, liquids and pills to obtain useful effects of preventing or alleviating hair loss.

[0195] Health functional foods can be prepared by methods commonly used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art during the preparation process. In addition, since health functional foods use food as raw materials, unlike general drugs, they have the advantage of not producing side effects that may occur when taking drugs for a long time, and can have excellent portability.

[0196] The following will provide preferred embodiments that are helpful for understanding the present invention. However, the following embodiments are provided only to make it easier to understand the present invention, and the content of the present invention is not limited by the following embodiments.

[0197] [Example]

[0198] Example 1. Induction of cell division and activation of hair dermal papilla cells and outer root sheath cells derived from human hair follicles by ALDH2 activation

[0199] To evaluate the effects of ALDH2 activators on hair follicle cell proliferation, human hair follicle-derived hair dermal papilla cells (HDPCs) and outer root sheath cells (ORS) were treated with 1 μM of the ALDH2 activator Alda-1 or the known hair loss treatment agent minoxidil, and CCK8 assays were performed. Primary cultured hair dermal papilla cells were treated with 0, 25, 50, or 100 μM Alda-1 and cultured for 24 or 48 hours, and then the cells were treated with CCK8 reagents and reacted at 37°C for 15 minutes. Then, the absorbance at 450 nm was measured using a photometer, and the extent of cell proliferation was confirmed by comparing the cells with the negative control and the positive control minoxidil.

[0200] The results confirmed that treatment with Alda-1 significantly increased the number of hair dermal papilla cells ( Figure 1a ) and outer root sheath cells ( Figure 1b ) cell viability. In particular, Alda-1 was found to promote the proliferation of hair dermal papilla cells and outer root sheath cells at a level comparable to or higher than minoxidil. These results support that activation of ALDH2 can promote the proliferation of hair dermal papilla cells and outer root sheath cells, and thus exhibit an effect of promoting hair regeneration.

[0201] Example 2: Confirmation of the effect of ALDH2 activation on promoting human hair follicle growth through human hair follicle organ culture experiment

[0202] In order to evaluate the effect of ALDH2 activation on the growth of human hair follicles, a human hair follicle organ culture (ex vivo hair follicle organ culture) test was performed. For the human hair follicle organ culture test, scalp tissue obtained from a voluntary donor was separated into follicular units, the part below the sebaceous gland of each separated hair follicle was cut off, and the remaining hair follicle was used. After the hair follicles were cultured by adding a culture medium containing a negative control reagent, 1 μM minoxidil, or 5, 25 or 50 μM Alda-1 (ALDH2 activator) to the prepared hair follicles, the length of the growing hair was measured on the 3rd and 6th days and compared with the negative control to confirm the effect of the ALDH2 activator on promoting hair growth in human hair follicles.

[0203] The results are as follows Figure 2a As shown, it was confirmed that activation of ALDH2 in the Alda-1 treated group promoted the elongation of hair in human hair follicles. In particular, Alda-1 was found to promote the growth of hair in hair follicles at a higher level than minoxidil.

[0204] In addition, in order to confirm the proliferation of cells in the cultured hair follicles through the experiment, immunofluorescence staining was performed using a cell division marker Ki-67 antibody. Hair follicles were treated with negative control, 1 μM minoxidil or Alda-1 and cultured for 2 days to prepare tissue sections, which were cut into 4 μm thick and fixed on slides, and then treated with Ki-67 as a primary antibody and a fluorescent protein-conjugated secondary antibody to detect Ki-676, and then observed and photographed under a fluorescence microscope to confirm the number of Ki-67-positive cells. The cell nucleus was stained with DAPI reagent.

[0205] The results are as follows Figure 2b As shown (Ki-67, red fluorescence; and DAPI, blue fluorescence). Figure 2b As can be seen in the figure, as ADLH2 is activated in hair follicles treated with Alda-1, the level of Ki-67 positive cells, i.e. cells that are dividing (proliferating), in the hair follicles increases, and it was found that this effect of Alda-1 is even better than minoxidil.

[0206] The above results indicate that activation of ALDH2 can promote the proliferation of cells in human hair follicles, thereby promoting hair growth.

[0207] Example 3. Confirmation of the effect of ALDH2 activation on the anagen phase of hair growth induction

[0208] To confirm the effect of ALDH2 activation on hair growth, the anagen induction effect of hair growth was confirmed using the C57BL / 6 mouse model. Although human hair has different hair cycles depending on the individual, in mice, all hair has the same cycle early in its life, and at 7 to 8 weeks of age, all hair enters the telogen phase and then transitions to the anagen phase. In order to evaluate the effect of ALDH2 activators on anagen induction using these characteristics of mice, the backs of 8-week-old C57BL / 6 mice in the telogen state were hair removed, and then the ALDH2 activator Alda-1 was applied once a day at a dose of 0.5mM or 3mM for three weeks, and the presence or absence of hair growth and the degree of anagen induction were confirmed by comparison with the negative control and the positive control (minoxidil weight %; 111mM).

[0209] The results are as follows Figure 3 As shown, in the Alda-1 treated group, the percentage of the area with anagen hair growth increased significantly, confirming that activation of ALDH2 has the effect of promoting anagen hair induction. In particular, although the Alda-1 treated group was treated with a much lower dose of the drug, its hair growth level was similar to or higher than that of the minoxidil treated group.

[0210] In addition, skin tissues with growing hair in the anagen phase were fixed in paraffin and stained with hematoxylin and eosin for histological examination. Figure 4 As shown, it can be confirmed that hair follicle formation was also promoted in the Alda-1-treated group, and its level was similar to that of the positive control treated with minoxidil.

[0211] In addition, the results of measuring the growth phase induction level and skin thickness of each mouse showed that the growth phase induction score and skin thickness of the ALDH2 activator-treated group were increased compared with those of the control group. Figure 5a and 5b shown.

[0212] These results suggest that activation of ALDH2 promotes hair growth by inducing the anagen phase of hair.

[0213] Example 4. Confirmation of the regulatory effect of ALDH2 activation on hair growth promoting protein

[0214] In order to confirm the molecular biological mechanism by which ALDH2 activation promotes the proliferation of hair dermal papilla cells and outer root sheath cells and induces the growth phase of hair follicles, changes in the protein levels of hair growth promoting factors caused by ALDH2 activation were confirmed using human hair dermal papilla cells. For this purpose, an enzyme-linked immunosorbent assay (ELISA) method was performed. After the hair dermal papilla cells cultured in the laboratory were treated with negative control or ALDH2 activator Alda-1 for 24 hours, the cell culture medium was collected and concentrated. The level of growth promoting protein was confirmed in the concentrated culture medium.

[0215] The results are as follows Figure 6 As shown, it can be confirmed that the levels of proteins such as basic fibroblast growth factor (bFGF), keratinocyte growth factor (FGF-7), insulin-like growth factor 1 (IGF-1), and platelet-derived growth factor (PDGF), which are known as hair growth promoting factors, are increased in the samples treated with the ALDH2 activator.

[0216] The above results indicate that activation of ALDH2 increases the protein level of hair growth promoting factor, thereby promoting the proliferation of cells associated with hair growth and inducing the growth phase of hair follicles.

[0217] Example 5. Confirmation of reduction of oxidative stress in human hair follicle-derived hair dermal papilla cells and outer root sheath cells by ALDH2 activation

[0218] Oxidative stress in hair follicle cells is known to inhibit the growth of hair follicles and hair and has an adverse effect on hair loss. Therefore, to evaluate the effect of ALDH2 activation on oxidative stress in hair follicle cells, human hair follicle-derived hair dermal papilla cells and outer root sheath cells were treated with the ALDH2 activator Alda-1, and 2',7'-dichlorofluorescein diacetate (DCFDA) assay was performed to confirm the degree of oxidative stress. The cultured cells in each group were treated with H2O2 to increase the level of oxidative stress, and the experimental groups were treated with ALDH2 activator Alda-1 at a concentration of 5, 25, or 50 μM for 3 hours to observe the expression of DCFDA. Further, the same experiment was performed by flow cytometry to confirm the expression level of DCFDA.

[0219] The results are as follows Figure 7 As shown, the fluorescence level indicating DCFDA in the Alda-1 treated group was significantly reduced compared to the untreated control, confirming that the ALDH2 activator reduced oxidative stress. In particular, oxidative stress was shown to be reduced in proportion to the treatment concentration of Alda-1, confirming that the ALDH2 activator is very effective in reducing oxidative stress in hair follicle cells. Flow cytometry results also showed that oxidative stress in outer root sheath cells was significantly reduced in proportion to the treatment concentration of Alda-1 ( Figure 8a and8b ).

[0220] The above results suggest that activating ALDH2 can reduce oxidative stress in hair follicle cells (oxidative stress is one of the main causes of hair loss), thereby reducing the risk of hair loss and promoting hair growth.

[0221] In particular, the above results show that the activation of aldehyde dehydrogenase 2 can not only promote hair growth, but also inhibit the occurrence of gray hair. In particular, gray hair is mainly caused by the reduction of pigment production due to the aging of melanocytes and the loss of melanocytes due to the production of reactive oxygen species. Tyrosinase in melanocytes mediates the process of tyrosine oxidation to DOPA in the melanin synthesis step, which occurs periodically in hair to produce melanin.

[0222] However, reactive oxygen species are generated during melanogenesis, and when reactive oxygen species accumulate, the antioxidant system is damaged and induces oxidative stress as the cell aging process progresses. Melanocytes are susceptible to excessive accumulation of oxidative stress. In particular, it is known that accumulated oxidative stress may disrupt the homeostasis of melanocytes, thereby inducing cell death or deformation.

[0223] Therefore, in order to inhibit the occurrence of gray hair, it is particularly important to reduce the exposure of melanocytes to reactive oxygen species. The present inventors have confirmed through the above examples that the activation of aldehyde dehydrogenase 2 is a mechanism that significantly reduces oxidative stress in human hair follicle cells. Therefore, after treatment with an aldehyde dehydrogenase 2 activator, the reactive oxygen species generated during the activation of melanocytes can be reduced, thereby effectively inhibiting damage to melanocytes and the occurrence of gray hair caused by aging.

[0224] Example 6. Confirmation of the expression of ALDH2 and mitochondria in human hair follicles during the growth phase and the resting phase

[0225] To confirm the changes in ALDH2 in hair follicles with the resting and growing phases, immunofluorescence staining was performed on tissues from patients with hair loss and healthy subjects. To identify aldehyde dehydrogenase 2 located in mitochondria, antibodies targeting the mitochondrial outer membrane protein marker "voltage-dependent anion channel (VDAC)" (anti-VDAC) and aldehyde dehydrogenase 2 antibodies (anti-ALDH2) were used. Each tissue was cut into 4 μm thickness and then treated with anti-VDAC and anti-ALDH2 as primary antibodies and fluorescently labeled secondary antibodies. The cell nuclei were stained with DAPI reagent, and then observed and photographed under a fluorescence microscope to confirm the number of VDAC and ALDH2 positive cells.

[0226] The results are as follows Figure 9a and 9bAs shown (in the fluorescent image, VDAC, green fluorescence; ALDH2, red fluorescence; DAPI, blue fluorescence). Hair follicles in the resting phase were observed in the tissues of patients with hair loss, while hair follicles in the growth phase could be observed in the tissues of healthy subjects. In human hair follicles, markers for the mitochondrial outer membrane and aldehyde dehydrogenase 2 are present in the same location. In addition, it can be confirmed that the expression of aldehyde dehydrogenase 2 in the outer root sheath cells is higher than that in the hair dermal papilla cells. Even when the proportion of aldehyde dehydrogenase 2-expressing cells located in the outer root sheath cells was confirmed again, it was similarly confirmed that the proportion was significantly increased in the hair follicles in the growth phase ( Figure 9b ).

[0227] The above results indicate that the interaction between aldehyde dehydrogenase 2 and mitochondria in hair follicle cells is related to the maintenance of the hair follicle growth phase and hair growth.

[0228] Example 7. Confirmation of changes in mitochondrial activity in outer root sheath cells derived from human hair follicles

[0229] To confirm the changes in mitochondrial activity in human hair follicle-derived outer root sheath cells with aldehyde dehydrogenase 2 activity, oxygen consumption rate was measured. 3 After cells / well were seeded into XF96 plates, the control group was treated with DMSO and the experimental group was treated with Alda-1 (25 μM). After 12 hours, the dissolved oxygen concentration in the culture medium during cell culture was measured using a real-time cell metabolism analyzer (Seahorse XFE96 analyzer). The cells were washed twice with substrate oxidation assay medium (XF DMEM pH 7.4 and 10 mM XF glucose, 1 mM XF pyruvate and 2 mM XF glutamine) and cultured at 37°C without CO2 for 60 minutes. The oxygen consumption efficiency of the outer root sheath cells was measured after oligomycin (1.5 μM), FCCP (1.5 μM) and rotenone / antimycin A (final concentration of each = 0.5 μM) were injected sequentially into the ports of the XF96 plate.

[0230] The results are as follows Fig.10a As shown in the results, it was confirmed that after treatment with Alda-1, the oxygen consumption efficiency of the outer root sheath cells increased as aldehyde dehydrogenase 2 was activated, thereby increasing mitochondrial activity. In addition, the basal respiration rate of the outer root sheath cells treated with Alda-1 increased significantly ( Fig.10b ), the maximum respiratory rate also increased significantly ( Fig.10c In addition, mitochondrial ATP production increased nearly 10-fold after treatment with Alda-1 ( Fig.10d ).

[0231] These results support that activation of ALDH2 promotes hair growth by enhancing mitochondrial function and inducing the growth phase of hair follicles.

[0232] As described above, since it has been confirmed that activation of ALDH2 can achieve excellent hair growth and hair regeneration promoting effects, it is expected that various ALDH2 activators will be used as agents for preventing, alleviating and / or treating hair loss. In particular, since it has been confirmed that Alda-1 according to an embodiment of the present invention can effectively induce hair follicles and hair growth even at a much smaller dose than minoxidil, a hair loss therapeutic agent in the related art, it is expected that Alda-1 can be used as a safer and more economical hair loss therapeutic agent.

[0233] In addition, it has been confirmed that the activation of ALDH2 in hair follicles and the interaction with mitochondria can contribute to the induction of the growth phase of hair follicles and promote hair growth. In particular, it has been confirmed that the activation of ALDH2 is a mechanism that can effectively inhibit oxidative stress in hair follicles. Therefore, the activation of ALDH2 can not only induce hair growth by reducing oxidative stress in hair follicles, but also effectively inhibit the occurrence of gray hair.

[0234] Example 8. Confirmation of the combined effect of ALDH2 activator and minoxidil

[0235] Since it has been confirmed in the previous examples that the ALDH2 activator can promote cell division in hair follicles and induce hair growth, the hair loss treatment effect caused by the combined use of the ALDH2 activator and minoxidil was confirmed in this example.

[0236] Specifically, in order to confirm the hair growth effect caused by the combined use of ALDH2 activator Alda-1 and minoxidil, it was confirmed whether the hair growth phase was induced after the two substances were co-administered to the C57BL / 6 mouse model. After shaving the hair on the back of eight-week-old C57BL / 6 mice in the resting phase, Alda-1 and / or minoxidil were applied to the following groups: untreated control; Alda-1 (3mM) single treatment group; 2% minoxidil single treatment group; and 3mM Alda-1 and 2% minoxidil combined treatment group. The combined treatment group was applied with a drug mixed with 3mM Alda-1 and 2% minoxidil. In the above-mentioned mixed drug, Alda-1 and minoxidil were mixed at a weight ratio of 1:37. For both the single treatment group and the combined treatment group, a dose of 200μl of the drug was applied each time. Each drug or drug mixture was applied to the back of mice once a day for three weeks, and the presence or absence of hair growth and the degree of induction of the growth phase were confirmed by comparison with the control group.

[0237] The results are as follows Fig.11 As shown, all mice treated with each drug alone or in combination showed hair growth compared with the control group, especially the group treated with Alda-1 and minoxidil in combination showed a much larger area of ​​anagen hair growth than the group treated with each drug alone.

[0238] In addition, skin tissue at the hair growth site during the growth phase was fixed in paraffin and subjected to immunofluorescence staining to confirm "versican," a marker of hair dermal papilla cells involved in hair formation and growth. The results showed that a much stronger signal was detected in the group treated with Alda-1 and minoxidil compared to the group treated with Alda-1 or minoxidil alone, confirming a significant increase in the number of hair dermal papilla cells.

[0239] The above results indicate that Alda-1 itself has an excellent hair loss treatment effect, and especially when Alda-1 is used in combination with minoxidil, it can exert a synergistic hair loss treatment effect by further enhancing the promotion of anagen induction and the formation of hair follicles.

[0240] As described above, since it has been confirmed that activation of ALDH2 can achieve excellent hair growth and hair regeneration promoting effects, it is expected that various ALDH2 activators will be used as agents for preventing, alleviating and / or treating hair loss. In particular, since it has been confirmed that Alda-1 according to an embodiment of the present invention can effectively induce hair follicles and hair growth even at a much smaller dose than minoxidil, a hair loss therapeutic agent in the related art, it is expected that Alda-1 can be used as a safer and more economical hair loss therapeutic agent.

[0241] Furthermore, since it has been confirmed that when ALDH2 and minoxidil are used in combination, the formation of hair follicles and the growth of hair are more significantly enhanced than when each drug is used alone, the use of ALDH2 in combination with minoxidil can achieve a better hair loss treatment effect. In particular, when the ALDH2 of the present invention is used, the amount of minoxidil used, which has the risk of causing side effects, can be reduced, so it is expected that safer and better hair loss treatment can be achieved.

[0242] The above description of the present invention is for illustrative purposes only, and those skilled in the art will appreciate that the present invention can be easily modified into other specific forms without changing the technical spirit or basic features of the present invention. Therefore, it should be understood that the above embodiments are illustrative in all aspects only and not restrictive.

[0243] [Industrial Applicability]

[0244] The present invention relates to a composition for preventing, alleviating and / or treating hair loss or white hair (or white hair disease), etc., and is accomplished by confirming that an aldehyde dehydrogenase 2 (ALDH2) activator promotes hair follicle formation and hair growth and has an excellent effect of inhibiting oxidative stress of hair follicles. Therefore, the ALDH2 activator according to the present invention can be used as a preparation for preventing, alleviating and / or treating hair loss and white hair, and shows a better hair loss prevention and treatment effect when used in combination with minoxidil. Therefore, the ALDH2 of the present invention not only has an effective hair growth promoting effect by itself, but is also expected to be effectively used in combination with minoxidil in the medical, beauty and food fields for preventing, alleviating and treating hair loss.

Claims

1. A pharmaceutical composition for preventing or treating hair loss or graying of hair, the composition comprising an aldehyde dehydrogenase 2 (ALDH2) activator as an active ingredient.

2. The pharmaceutical composition according to claim 1, wherein the composition is used to promote hair growth or hair regeneration.

3. The pharmaceutical composition according to claim 1, wherein the hair loss is any one or more selected from the group consisting of alopecia areata, hereditary androgenic alopecia, telogen effluvium, traumatic alopecia, trichotillomania, compression alopecia, anagen effluvium, pityriasis alopecia, syphilitic alopecia, seborrheic alopecia, symptomatic alopecia and congenital alopecia. The pharmaceutical composition according to claim 1 , wherein the aldehyde dehydrogenase 2 activator is Alda-1 or a pharmaceutically acceptable salt thereof. 5 . The pharmaceutical composition according to claim 4 , wherein the Alda-1 or a pharmaceutically acceptable salt thereof is contained in a concentration of 0.0001 to 50 mM relative to the composition.

6. The pharmaceutical composition according to claim 1, wherein the composition satisfies one or more characteristics selected from the group consisting of: (a) Promote the proliferation of hair dermal papilla cells or outer root sheath cells; (b) Promote the growth of hair follicles; (c) inducing the growth phase of hair; and (d) Increase mitochondrial activity.

7. The pharmaceutical composition according to claim 1, wherein the composition increases the level or activity of one or more proteins selected from the group consisting of bFGF, FGF-7, IGF-1 and PDGF.

8. The pharmaceutical composition of claim 1, wherein the compound reduces oxidative stress in hair dermal papilla cells or outer root sheath cells.

9. A cosmetic composition for preventing or alleviating hair loss or graying of hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient.

10. The cosmetic composition according to claim 9, wherein the composition is an external preparation in the form of a scalp care agent, soap, hair tonic, shampoo, hair dye, hair mask, hair gel, lotion, hair conditioner, hair oil, mousse, cream, solid, solution, emulsion, dispersion, micelle, liposome, ointment, perfume, essential oil, patch or spray.

11. A quasi-drug composition for preventing or alleviating hair loss or graying of hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient.

12. A food composition for preventing or alleviating hair loss or graying of hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient.

13. A health functional food composition for preventing or alleviating hair loss or graying of hair, the composition comprising an aldehyde dehydrogenase 2 activator as an active ingredient.

14. A pharmaceutical composition for preventing or treating hair loss, comprising an aldehyde dehydrogenase 2 activator as an active ingredient, wherein the pharmaceutical composition is administered in combination with minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

15. The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition and the minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof are administered simultaneously or sequentially.

16. The pharmaceutical composition according to claim 14, wherein the aldehyde dehydrogenase 2 activator enhances the hair loss therapeutic effect of the minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof. 17 . The pharmaceutical composition according to claim 14 , wherein the aldehyde dehydrogenase 2 activator is Alda-1 or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition for preventing or treating hair loss, comprising as active ingredients: (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof. The pharmaceutical composition according to claim 18 , wherein the aldehyde dehydrogenase 2 activator is Alda-1 or a pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition according to claim 18, wherein the composition is in the form of a mixed preparation, wherein (a) the aldehyde dehydrogenase 2 activator; and (b) the minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof are mixed.

21. The pharmaceutical composition according to claim 18, wherein the composition is in a form in which (a) the aldehyde dehydrogenase 2 activator and (b) the minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof are each formulated and administered simultaneously, separately or sequentially.

22. A cosmetic composition for preventing or alleviating hair loss, comprising as active ingredients: (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

23. The cosmetic composition according to claim 22, wherein the composition is an external preparation in the form of a scalp care agent, soap, hair tonic, shampoo, hair dye, hair mask, hair gel, lotion, hair conditioner, hair oil, mousse, cream, solid, solution, emulsion, dispersion, micelle, liposome, ointment, perfume, essential oil, patch or spray.

24. A quasi-drug composition for preventing or alleviating hair loss, comprising as active ingredients: (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

25. A food composition for preventing or alleviating hair loss, comprising as active ingredients: (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

26. A health functional food composition for preventing or alleviating hair loss, the composition comprising the following as active ingredients: (a) an aldehyde dehydrogenase 2 activator and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof.

27. A method for preventing, alleviating or treating hair loss or graying of hair, the method comprising administering an aldehyde dehydrogenase 2 activator to a subject in need thereof.

28. Use of an aldehyde dehydrogenase 2 activator for preventing, alleviating or treating hair loss or graying of hair.

29. Use of an aldehyde dehydrogenase 2 activator for preparing a medicament for preventing, alleviating or treating hair loss or graying of hair.

30. A method for preventing or treating hair loss, comprising administering to a subject in need thereof (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof, or an analog thereof.

31. Use of a composition for preventing, alleviating or treating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analog thereof.

32. Use of a composition for preparing a medicament for preventing, alleviating or treating hair loss, the composition comprising (a) an aldehyde dehydrogenase 2 activator; and (b) minoxidil, a pharmaceutically acceptable salt thereof or an analogue thereof.